Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BBIO 
BridgeBio Pharma Inc (BBIO)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/28/2025: BBIO (5-star) is a STRONG-BUY. BUY since 149 days. Simulated Profits (97.72%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $84.65
1 Year Target Price $84.65
| 10 | Strong Buy |
| 6 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 127.43% | Avg. Invested days 41 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 13.88B USD | Price to earnings Ratio - | 1Y Target Price 84.65 |
Price to earnings Ratio - | 1Y Target Price 84.65 | ||
Volume (30-day avg) 19 | Beta 1.27 | 52 Weeks Range 25.34 - 72.28 | Updated Date 11/29/2025 |
52 Weeks Range 25.34 - 72.28 | Updated Date 11/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -225.32% | Operating Margin (TTM) -112.97% |
Management Effectiveness
Return on Assets (TTM) -43.48% | Return on Equity (TTM) -1789.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 15090756624 | Price to Sales(TTM) 39.22 |
Enterprise Value 15090756624 | Price to Sales(TTM) 39.22 | ||
Enterprise Value to Revenue 42.66 | Enterprise Value to EBITDA -9.4 | Shares Outstanding 192708813 | Shares Floating 155280907 |
Shares Outstanding 192708813 | Shares Floating 155280907 | ||
Percent Insiders 4.72 | Percent Institutions 100 |
Upturn AI SWOT
BridgeBio Pharma Inc
Company Overview
History and Background
BridgeBio Pharma Inc. was founded in 2015 to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. It's evolved through various clinical trials and regulatory milestones.
Core Business Areas
- Drug Development: Focuses on developing therapies for genetic diseases and genetically driven cancers.
Leadership and Structure
Neil Kumar serves as the CEO. The company has a board of directors and operates with a functional structure, focused on research, development, and commercialization.
Top Products and Market Share
Key Offerings
- NULIBRY (fosdenopterin): Treatment for molybdenum cofactor deficiency (MoCD) Type A, a rare metabolic disorder. Revenue is growing, but specific market share data is limited due to the rarity of the condition. Competitor: None currently approved specifically for MoCD Type A.
- TRUSELTIQ (infigratinib): Treatment for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. Competitors: Pemigatinib (Pemazyre) and Futibatinib (Lytgobi).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. The focus on genetic diseases is a growing area with significant unmet needs.
Positioning
BridgeBio is positioned as a company specializing in genetic diseases and genetically defined cancers with a focus on rapid development and commercialization of targeted therapies.
Total Addressable Market (TAM)
The TAM for genetic diseases and genetically driven cancers is significant, estimated to be in the tens of billions of dollars annually. BridgeBio is positioning itself to capture a portion of this market through targeted therapies.
Upturn SWOT Analysis
Strengths
- Strong focus on genetic diseases
- Experienced management team
- Diverse pipeline of drug candidates
- Strategic partnerships and collaborations
Weaknesses
- High R&D costs
- Dependence on clinical trial success
- Potential regulatory hurdles
- Reliance on external funding
Opportunities
- Expansion into new genetic disease areas
- Acquisition of promising drug candidates
- Strategic partnerships with larger pharmaceutical companies
- Accelerated regulatory pathways for rare diseases
Threats
- Clinical trial failures
- Competition from other pharmaceutical companies
- Changes in regulatory environment
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- PFE
- BMY
- MRK
- LLY
Competitive Landscape
BridgeBio is a smaller player compared to major pharmaceutical companies. Its competitive advantage lies in its specialization in genetic diseases and genetically defined cancers.
Growth Trajectory and Initiatives
Historical Growth: BridgeBio has experienced growth through acquisitions and advancement of its drug pipeline.
Future Projections: Analysts project continued revenue growth driven by commercialization of existing products and potential approval of new therapies.
Recent Initiatives: Focus on advancing key clinical programs, strategic partnerships, and potential acquisitions.
Summary
BridgeBio is a growing biopharmaceutical company specializing in genetic diseases with a strong focus on drug development. Its revenue is growing but it also faces high R&D expenses. Clinical trial outcomes, competition from other pharmaceutical companies, and the regulatory environment pose significant risks. The company must manage its cash flow effectively and secure additional funding to continue its operations.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC), Analyst reports, Market research reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BridgeBio Pharma Inc
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2019-06-27 | Co-Founder, CEO & Director Dr. Neil Kumar Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 725 | Website https://bridgebio.com |
Full time employees 725 | Website https://bridgebio.com | ||
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.